COHANCE stock news on Anadi Algo News

Monday, June 15, 2026
DISCLAIMER: AI-generated signals are for informational purposes only. All trading and investment decisions are solely the user's responsibility.|Past performance does not guarantee future results. Trade at your own risk.|Anadi Algo is not a SEBI-registered advisor. Consult a qualified financial advisor before acting on any recommendation.|DISCLAIMER: AI-generated signals are for informational purposes only. All trading and investment decisions are solely the user's responsibility.|Past performance does not guarantee future results. Trade at your own risk.|Anadi Algo is not a SEBI-registered advisor. Consult a qualified financial advisor before acting on any recommendation.|
Stock Landing|7 matching stories

COHANCE Share Price, Latest News & Sentiment

Latest AI-analyzed news for COHANCE, along with saved share-price context, sentiment, quarterly filing summary, and related names in one page.

Stock Coverage Hub

COHANCE News Today

Active stock coverage

The broader market is currently experiencing downward pressure, with Sensex and Nifty trading lower, indicating a cautious sentiment. This makes individual stock-specific negative news, like Cohance Lifesciences', more impactful.

Coverage
7
recent stories
Sources
2
distinct publishers
Bias Split
4 bullish / 2 bearish
1 neutral stories
Window
16d
recent coverage span
Saved Quote Snapshot

COHANCE

Last Updated
23 May 2026
Price
NA
NA
52W Range
NA - NA
exchange snapshot
PE / VWAP
PE NA
VWAP NA
Trend Read
mixed
EMA stack mixed
Business Context
Industry: NA
Sector Trail: NA
Listing Date: NA
Market Structure
F&O Eligible: No
Indices: NA
Snapshot Source: mcp+nse
Quarterly Read

Quarter ended 31 Dec 2024

Consolidated results
What This Quarter Says

This is the first public financial report for COHANCE. The company reported revenues of Rs 307.15 crore and a profit of Rs 83.29 crore. This filing provides the initial financial snapshot of the company's performance.

Revenue
Rs 307.15 cr
up 11.5% vs previous filing
Profit
Rs 83.29 cr
down 3.5% vs previous filing
EPS / Finance Cost
EPS 3.26
Finance cost Rs 3.33 cr
Filing Context
Filed 13 Feb 2025, 9:40 pm
Figures are taken from the saved exchange filing, not from a live request.
Quick Reader Notes
  • Revenue this quarter: Rs 307.15 cr, up 11.5% vs previous filing.
  • Profit this quarter: Rs 83.29 cr, down 3.5% vs previous filing.
  • EPS gives a quick sense of per-share earnings: 3.26.
How To Read This

Treat this block as a saved quarter snapshot. First see whether revenue and profit are improving, then read the latest news below to judge whether recent headlines support that trend or work against it.

COHANCE FAQ

Why is COHANCE in the news right now?

COHANCE has appeared across 7 recent stories from 2 sources, which usually means there is a real flow of fresh headlines rather than a single isolated mention.

Is COHANCE coverage bullish or bearish right now?

COHANCE coverage is currently leaning bullish, with 4 bullish, 2 bearish, and 1 neutral analyzed stories in the recent window.

Which themes are moving with COHANCE?

Recent COHANCE coverage is clustering around Pharmaceuticals and Healthcare. Related names showing up alongside COHANCE include CIPLA, AXISBANK, CANBK.

How should I use this COHANCE news page?

Use this page as a coverage hub for COHANCE: start with the latest headlines, then check the dominant themes, related names, and saved market context before you form a trade or watchlist view.

Workflow View

Use COHANCE coverage to build a cleaner watchlist.

A stock page is most useful when it helps you slow down, compare headlines, and separate one-off noise from a repeatable setup.

This is here if you want to go deeper, not as a push.Explore Anadi
Maintain a bearish bias on Cohance Lifesciences in the short term, with strict stop-losses, given the weak fundamentals and analyst downgrade.|Quick check: NIFTY neutral, SENSEX neutral.
et_marketsabout 1 month ago

F&O Talk: Nifty charts suggest further consolidation; Sudeep Shah's strategy on Cohance, HEG and 4 more stocks

The banking sector is currently facing headwinds, with several major banks experiencing declines. This weakness is a key factor contributing to the Nifty's consolidation, as banking heavyweights often influence overall market direction.

Maintain a cautious stance on banking stocks, focusing on companies with strong asset quality and deposit growth. For smallcaps, look for fundamentally sound companies with clear growth catalysts, using strict stop-losses.|Quick check: INDIANB bearish bias (oversold), AXISBANK bearish bias (oversold).

Latest COHANCE Stock Coverage

Long bias for Cohance Lifesciences; look for consolidation after the initial surge for potential entry points.|Quick check: COHANCE bullish bias (overbought), CIPLA bullish bias (overbought).
For banking, consider a cautious approach; long positions in banks demonstrating strong NIMs and asset quality, and short positions or avoidance for those showing weakness, with strict stop-losses.|Quick check: INDUSINDBK bullish bias (overbought), AXISBANK bearish bias (-2.7% 1d).
For Cohance Lifesciences, maintain a bullish bias, but set clear stop-losses given the sharp initial move. Look for consolidation or further positive news for entry points.|Quick check: CIPLA bullish bias (overbought), NIFTY neutral.